Scabies Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Type (Sulphur Ointment, Benzyl Benzoate Lotion, Lindane Lotion, Crotamiton Cream, Permethrin Cream, Others), By Route of Administration (Oral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Region Forecast 2020-2031

Scabies Treatment Market size was valued at US$ 237.5 million in 2024 and is expected to reach US$ 338.7 million by 2031, growing at a significant CAGR of 5.2% from 2025-2031. owing to the increased infestation of Scabies cases in hot, tropical countries and in areas of high population density. Scabies treatment includes a range of medications used to treat Scabies; a contagious itchy skin rash caused by a tiny burrowing mite called Sarcoptes scabies mite. Poverty, overcrowding, malnutrition, and lack of local expertise to recognize scabies leading to delayed diagnosis in underdeveloped and developing countries are major driving factors market. According to WHO 2023, 200 million people worldwide suffer from scabies at any one time, and more than 400 million people cumulatively every year. Moreover, rapid advancements in the healthcare and medical sector, high adoption of the latest tools and techniques, and growing funds by several public and private sectors have increased the opportunities for the advancement of the market. For instance, serology test and enzyme-linked immunosorbent assay (ELISA) in the last decade has proven to be highly sensitive (100%) and specific (97%) in identifying infected animals.

Furthermore, the shortage of drugs, vaccines, and medical supplies in hospitals is expected to offer industry players profitable growth opportunities in the coming years. Rising personal disposable income is another indirect element that will result in profitable market expansion potential. But, the abundance of homecare treatments and the unfavourable reimbursement environment in developing and underdeveloped economies along with high research and development expenses are expected to the growth of the market. However, the rising demand for targeted therapies, an increase in R&D activities for the creation of novel drugs and treatments, increased governmental awareness programs, a high prevalence of skin disorders, the disease's high contagiousness, and increased investments for the construction of healthcare infrastructure are some factors leading to the profitable growth of the market and is expected to flourish in the forecasted years.

Key Developments

• In August 2021, ParaPRO, a specialty pharma company focused on innovative anti-parasitic treatments, announced the launch of Natroba (spinosad) topical suspension.
• In April 2021, Spinosad topical suspension 0.9%, was approved by the Food and Drug Administration for treating scabies infestations in adult and paediatric patients 4 years of age and older – a first-in-class drug and the first new scabicide approved in 31 years.